Inventor · disambiguated record
Sarah J. Hatsell
Also filed as: HATSELL SARAH · HATSELL SARAH J · HATSELL SARAH JANE
11 granted patents·10 pending applications·25 citations·filing 2014–2024
87Inventor score
Files withREGENERON PHARMA21
Top patents by PatentIndex Score
21 records- 0194US9999207B2Nucleic acid construct for making a genetically modified rodent with an inducible ACVR1 mutation that causes ectopic bone formationREGENERON PHARMA·Filed 2016·Granted Jun 19, 2018·6 cites·3 claims
- 0294US9510569B2Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formationREGENERON PHARMA·Filed 2014·Granted Dec 6, 2016·12 cites·4 claims
- 0385US11407822B2Treatment of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2019·Granted Aug 9, 2022·2 cites·6 claims
- 0482US10531648B2Conditional rodent Acvr1 mutant geneREGENERON PHARMA·Filed 2018·Granted Jan 14, 2020·1 cites·7 claims
- 0582US10470444B2Method for making a genetically modified mouse with an inducible ACVR1 mutation that causes ectopic bone formationREGENERON PHARMA·Filed 2018·Granted Nov 12, 2019·1 cites·21 claims
- 0682US10448621B2Rodent embryonic stem cell with conditional ACVR1 mutant allelesREGENERON PHARMA·Filed 2018·Granted Oct 22, 2019·1 cites·13 claims
- 0781US11419319B2Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formationREGENERON PHARMA·Filed 2019·Granted Aug 23, 2022·2 cites·23 claims
- 0874US2024190974A1Anti-acvr1 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0973US12089576B2Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) geneREGENERON PHARMA·Filed 2022·Granted Sep 17, 2024·0 cites·12 claims
- 1071US2020229406A1Rodents With Conditional ACVR1 Mutant AllelesREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 1170USRE49121EGenetically modified mouse with an inducible ACVR1 gene with a mutant R206H exon 5 that has ectopic bone formationREGENERON PHARMA·Filed 2018·Granted Jul 5, 2022·0 cites·17 claims
- 1264US2021061898A1Treatment of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1363US11945872B2Anti-ACVR1 antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Apr 2, 2024·0 cites·21 claims
- 1460US12448435B2Anti-TMPRSS6 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Oct 21, 2025·0 cites·16 claims
- 1558US2024150474A1Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossificationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1657US2025295096A1A rodent model of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1756US2019153085A1Treatment of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 1852US2018111983A1Treatment of Fibrodysplasia Ossificans ProgressivaREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 1951US2022251184A1Human antibodies to bone morphogenetic protein 6REGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2048US2016319009A1Treatment of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 2147US2016075772A1Treatment of Fibrodysplasia Ossificans ProgressivaREGENERON PHARMA·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sarah J. Hatsell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →